PFIZER | TTK HEALTHCARE | PFIZER/ TTK HEALTHCARE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 48.7 | 10.7 | 456.0% | View Chart |
P/BV | x | 8.1 | 1.6 | 521.5% | View Chart |
Dividend Yield | % | 0.4 | 1.0 | 42.4% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PFIZER Mar-19 |
TTK HEALTHCARE Mar-19 |
PFIZER/ TTK HEALTHCARE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,840 | 1,215 | 316.0% | |
Low | Rs | 2,080 | 610 | 340.9% | |
Sales per share (Unadj.) | Rs | 455.0 | 444.4 | 102.4% | |
Earnings per share (Unadj.) | Rs | 93.8 | 17.2 | 543.8% | |
Cash flow per share (Unadj.) | Rs | 109.4 | 27.6 | 395.9% | |
Dividends per share (Unadj.) | Rs | 22.50 | 5.00 | 450.0% | |
Dividend yield (eoy) | % | 0.8 | 0.5 | 138.7% | |
Book value per share (Unadj.) | Rs | 658.2 | 177.9 | 369.9% | |
Shares outstanding (eoy) | m | 45.75 | 14.13 | 323.8% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.5 | 2.1 | 316.8% | |
Avg P/E ratio | x | 31.6 | 52.9 | 59.7% | |
P/CF ratio (eoy) | x | 27.1 | 33.0 | 81.9% | |
Price / Book Value ratio | x | 4.5 | 5.1 | 87.7% | |
Dividend payout | % | 24.0 | 29.0 | 82.8% | |
Avg Mkt Cap | Rs m | 135,420 | 12,894 | 1,050.2% | |
No. of employees | `000 | 2.6 | 2.3 | 113.8% | |
Total wages/salary | Rs m | 3,238 | 1,307 | 247.8% | |
Avg. sales/employee | Rs Th | 7,911.4 | 2,715.7 | 291.3% | |
Avg. wages/employee | Rs Th | 1,230.9 | 565.3 | 217.7% | |
Avg. net profit/employee | Rs Th | 1,630.7 | 105.4 | 1,547.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 20,815 | 6,279 | 331.5% | |
Other income | Rs m | 1,674 | 78 | 2,159.9% | |
Total revenues | Rs m | 22,489 | 6,356 | 353.8% | |
Gross profit | Rs m | 5,712 | 496 | 1,152.5% | |
Depreciation | Rs m | 714 | 147 | 486.6% | |
Interest | Rs m | 73 | 34 | 215.7% | |
Profit before tax | Rs m | 6,599 | 393 | 1,680.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,309 | 149 | 1,550.4% | |
Profit after tax | Rs m | 4,291 | 244 | 1,760.6% | |
Gross profit margin | % | 27.4 | 7.9 | 347.7% | |
Effective tax rate | % | 35.0 | 37.9 | 92.2% | |
Net profit margin | % | 20.6 | 3.9 | 531.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,167 | 2,717 | 999.8% | |
Current liabilities | Rs m | 8,917 | 1,571 | 567.7% | |
Net working cap to sales | % | 87.7 | 18.3 | 480.2% | |
Current ratio | x | 3.0 | 1.7 | 176.1% | |
Inventory Days | Days | 68 | 32 | 210.9% | |
Debtors Days | Days | 30 | 47 | 64.5% | |
Net fixed assets | Rs m | 8,862 | 991 | 894.2% | |
Share capital | Rs m | 458 | 141 | 323.8% | |
"Free" reserves | Rs m | 29,656 | 2,373 | 1,249.7% | |
Net worth | Rs m | 30,113 | 2,514 | 1,197.7% | |
Long term debt | Rs m | 25 | 3 | 735.3% | |
Total assets | Rs m | 39,400 | 4,158 | 947.5% | |
Interest coverage | x | 91.5 | 12.6 | 725.5% | |
Debt to equity ratio | x | 0 | 0 | 61.4% | |
Sales to assets ratio | x | 0.5 | 1.5 | 35.0% | |
Return on assets | % | 11.1 | 6.7 | 165.9% | |
Return on equity | % | 14.2 | 9.7 | 147.0% | |
Return on capital | % | 22.1 | 16.9 | 130.7% | |
Exports to sales | % | 0 | 3.6 | 0.0% | |
Imports to sales | % | 0 | 0.5 | 0.0% | |
Exports (fob) | Rs m | NA | 225 | 0.0% | |
Imports (cif) | Rs m | NA | 31 | 0.0% | |
Fx inflow | Rs m | 428 | 225 | 190.2% | |
Fx outflow | Rs m | 786 | 71 | 1,105.9% | |
Net fx | Rs m | -358 | 154 | -232.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 978 | 173 | 565.0% | |
From Investments | Rs m | 351 | 97 | 363.9% | |
From Financial Activity | Rs m | -1,099 | -307 | 357.5% | |
Net Cashflow | Rs m | 231 | -38 | -612.2% |
Indian Promoters | % | 0.0 | 65.4 | - | |
Foreign collaborators | % | 63.9 | 0.0 | - | |
Indian inst/Mut Fund | % | 7.5 | 3.7 | 202.7% | |
FIIs | % | 4.9 | 5.2 | 94.2% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 23.7 | 25.8 | 91.9% | |
Shareholders | 85,207 | 12,723 | 669.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PFIZER With: SUVEN LIFE SCIENCES NEULAND LABS PIRAMAL ENTERPRISES FDC SUN PHARMA
Compare PFIZER With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 1,148 points, down 2.4% at 47,683 levels.
For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended December 2020, TTK HEALTHCARE has posted a net profit of Rs 77 m (up 71.7% YoY). Sales on the other hand came in at Rs 2 bn (up 8.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More